Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High on Analyst Upgrade

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price hit a new 52-week high during trading on Monday after Wedbush raised their price target on the stock from $59.00 to $72.00. Wedbush currently has an outperform rating on the stock. Kiniksa Pharmaceuticals International traded as high as $61.94 and last traded at $61.84, with a volume of 69222 shares changing hands. The stock had previously closed at $59.20.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Buy” and a consensus target price of $62.71.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the transaction, the chief accounting officer directly owned 27,418 shares in the company, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. This trade represents a 47.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 653,301 shares of company stock valued at $34,046,073 in the last quarter. Insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. Mark Sheptoff Financial Planning LLC boosted its position in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after purchasing an additional 250 shares in the last quarter. Mariner LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares during the last quarter. First Trust Advisors LP increased its position in shares of Kiniksa Pharmaceuticals International by 3.1% in the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares in the last quarter. Virtus Investment Advisers LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after buying an additional 406 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its stake in shares of Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after buying an additional 508 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Performance

The firm’s 50-day moving average is $52.17 and its 200 day moving average is $46.99. The firm has a market capitalization of $4.79 billion, a PE ratio of 69.16 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period last year, the firm posted $0.11 EPS. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.